Modulation of gastrointestinal function by MuDelta, a mixed µ opioid receptor agonist/ µ opioid receptor antagonist.
about
Mechanism-Oriented Therapy of Irritable Bowel SyndromeNew and emerging therapies for the treatment of irritable bowel syndrome: an update for gastroenterologistsThe Useage of Opioids and their Adverse Effects in Gastrointestinal Practice: A ReviewDisorders of gastrointestinal hypomotilityRifaximin and eluxadoline - newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron?Early response predicts a sustained response to eluxadoline in patients with irritable bowel syndrome with diarrhoea in two Phase 3 studies.Eluxadoline Efficacy in IBS-D Patients Who Report Prior Loperamide Use.Novel therapeutic agents in neurogastroenterology: advances in the past year.Recent advances in pharmacological treatment of irritable bowel syndrome.Putative kappa opioid heteromers as targets for developing analgesics free of adverse effects.Identification of a μ-δ opioid receptor heteromer-biased agonist with antinociceptive activity.Palmitoylethanolamide normalizes intestinal motility in a model of post-inflammatory accelerated transit: involvement of CB₁ receptors and TRPV1 channels.Heteromers of μ-δ opioid receptors: new pharmacology and novel therapeutic possibilities.Effect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadoline.Pharmacological traits of delta opioid receptors: pitfalls or opportunities?Current and emergent pharmacologic treatments for irritable bowel syndrome with diarrhea: evidence-based treatment in practice.Safety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea.Non-peptidic δ opioid receptor agonists and antagonists (2000 - 2012).Emerging drug for diarrhea predominant irritable bowel syndrome.Eluxadoline: First Global Approval.Drug discovery approaches to irritable bowel syndrome.Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers.Emerging treatments in neurogastroenterology: eluxadoline - a new therapeutic option for diarrhea-predominant IBS.Gastrointestinal dysmotility disorders in critically ill dogs and cats.Opioidergic effects on enteric and sensory nerves in the lower GI tract: basic mechanisms and clinical implications.The in vitro pharmacological profile of TD-1211, a neutral opioid receptor antagonist.Eluxadoline: A Review in Diarrhoea-Predominant Irritable Bowel Syndrome.The Delta Opioid Receptor in Pain Control.Abuse Potential and Pharmacodynamic Characteristics of Oral and Intranasal Eluxadoline, a Mixed μ- and κ-Opioid Receptor Agonist and δ-Opioid Receptor Antagonist.The place of eluxadoline in the management of irritable bowel syndrome with diarrhea.Pharmacological Approach for Managing Pain in Irritable Bowel Syndrome: A Review Article.Spotlight on eluxadoline for the treatment of patients with irritable bowel syndrome with diarrhea.Irritable bowel syndrome diagnosis and management: A simplified algorithm for clinical practice.New therapeutic options for IBS: the role of the first in class mixed µ- opioid receptor agonist and δ-opioid receptor antagonist (mudelta) eluxadoline.Insights into the Role of Opioid Receptors in the GI Tract: Experimental Evidence and Therapeutic Relevance.Eluxadoline in irritable bowel syndrome with diarrhea: rationale, evidence and place in therapy.Mu and delta opioid receptor knockout mice show increased colonic sensitivity.Methyl-orvinol-Dual activity opioid receptor ligand inhibits gastrointestinal transit and alleviates abdominal pain in the mouse models mimicking diarrhea-predominant irritable bowel syndrome.Effect of Hepatic Impairment on Eluxadoline Pharmacokinetics.Short-term oxycodone treatment does not affect electrogenic ion transport in isolated mucosa from the human rectosigmoid colon.
P2860
Q26747875-77505546-005E-4AE1-82E5-6573E6D4D607Q26748617-9307D1A7-DACE-4932-B4C5-6D0F9EEE4FC9Q26851158-7222B550-6BB1-4030-908D-E9344ECB90D8Q28070278-7DE346D0-E6E6-4107-B9EA-8BE3B01EAE52Q33466527-70D3998F-E621-47C2-B904-14607A3306F2Q33628494-88585839-8FF8-42D8-AA03-04C4B4964497Q33781174-227F13A6-9505-4783-91EE-EA8B44783086Q33934623-34439A2C-5A1C-4B98-B3AF-BA4AFCBD036AQ33958853-C0E863B7-F7DE-4E71-A3EA-6163B5B98F11Q34061067-8F38A9FF-3CDA-4ACA-931E-250ED164CEBFQ34354902-AE789382-637C-4CFA-ACB3-AA6C8C8F0D9BQ34571380-F0922998-F85D-47C4-B3DF-BE8C49F0B7B2Q34939624-08DBE767-4042-4321-A714-8EA4E1845CBFQ35468805-55A1E59D-AEF7-49A4-A09E-DD34DE25ECDCQ36920342-36CEEDFD-42E9-4E43-A3C5-226E5F03B134Q37632259-8DB42446-134A-4F13-A04C-81709E1C1E59Q37654528-14065643-2CDA-460A-BA9F-F3365E396890Q38109239-143ABABD-25FF-4ECD-AC0A-0D9D7C7F5517Q38366814-ECA5B36A-385D-4EDF-AC93-AE3D90C65BE5Q38543345-81C75987-E633-4E61-9204-2FCC679E7642Q38550878-B3C0E4AC-9659-4ADA-8765-89FE60FF6A7FQ38659429-95979260-CC32-4FF3-9871-B398A172515DQ38675489-F4C20B8D-F848-44DC-AF93-C214AAF0F90DQ38715379-E7DFA7D6-5058-41B0-969E-D02E7649726EQ38911748-E0464B14-1DFA-48E8-B179-2D7A482707DBQ39229690-896C6379-CCE6-40D8-B1D3-993B12C0F490Q39298126-88469B92-7E1B-4FBA-8BE5-152A65DE823EQ39310502-8A804261-C10C-4885-BA12-C3FA787AFD95Q39372153-D0BE1D83-FC76-4CBE-B0B2-7F85BEEFA266Q41078536-02FD377C-6F18-4BD3-9D9A-899A7E1D5194Q41392745-2B88A7AB-1375-49EE-96A9-9A23F06FE775Q42184351-8EF11DC8-84C7-4822-BE30-D9744EDDBE9AQ42284194-EB65E25C-8824-419F-BD79-8CBD64C7181EQ43062026-15982863-6206-4D8A-A156-A4666491E528Q43062074-CCBE09EC-5C24-44F6-A9D6-111BE827E02BQ43075643-1C37AD8F-01CA-4EDE-8974-FED227CA1AE9Q44340786-B94B354D-D277-458D-B9E9-D89A68B23FE1Q44343238-C637BFDE-A919-4E87-B74C-F6631A2EAA35Q50308630-E1D3A9F9-B09C-4671-88D0-47A3785D8650Q53263085-05B9BB36-FF39-4C0B-A448-09FF016E8280
P2860
Modulation of gastrointestinal function by MuDelta, a mixed µ opioid receptor agonist/ µ opioid receptor antagonist.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Modulation of gastrointestinal ...... µ opioid receptor antagonist.
@ast
Modulation of gastrointestinal ...... µ opioid receptor antagonist.
@en
type
label
Modulation of gastrointestinal ...... µ opioid receptor antagonist.
@ast
Modulation of gastrointestinal ...... µ opioid receptor antagonist.
@en
prefLabel
Modulation of gastrointestinal ...... µ opioid receptor antagonist.
@ast
Modulation of gastrointestinal ...... µ opioid receptor antagonist.
@en
P2093
P2860
P1476
Modulation of gastrointestinal ...... µ opioid receptor antagonist.
@en
P2093
C R Schneider
E S Kimball
H J Breslin
J M Palmer
K Chevalier
N H Wallace
P J Hornby
P R Saunders
P2860
P304
P356
10.1111/J.1476-5381.2012.02068.X
P407
P577
2012-11-01T00:00:00Z